KalshiKullanılabilirliği kontrol etKYC gerekliDoğrulanmış sonuçlanma verisiİyi kalibreSeçili emir defteri orta fiyatı
Before 2035 · —
Seçili emir defteri yükleniyor…
—
Kayıtlı fiyat
Before 2035 83.5%6 seçenek arasında lider
Before 2035 83.5%Piyasa kalitesi
35 / 100
Düşük kalite24s Hacim
—
Açık pozisyon
$329,3
Düşük açık pozisyonAlış / Satış
— / —
Before 2035Spread
—
Piyasa verileri
35 dakika önce güncellendi
27 May 26 14:00 UTC1 Oca 30 04:59 UTC
Grafik ve değişimler, seçili canlı emir defterini değil kayıtlı geçmiş olasılıkları gösterir.
Trendler
Seçili satır: emir defteri orta fiyatı. Diğer satırlar: normalleştirilmiş olabilen kayıtlı referanslar; 24 saatlik değişimler kayıtlı geçmişi kullanır.
İşlem platformu koşulları
Kaynak: Kalshi
Bu koşullar yalnızca bilgi amaçlıdır; CoinRithm deneme işlemlerinde kendi kurallarını uygular.
- Erken kapanış:
- Evet
- Sonuçlandırma süresi:
- 30m (bilgi amaçlı)
Piyasa derinliği · Before 2035
Seçili emir defteri yükleniyor…
—
İlgili Piyasalar
Bağlam için ilgili sorular; eşdeğer sözleşmelerin karşılaştırması değildir.
The FDA will approve an AI developed cure before the end of the decade (<2030) for a previously incurable major illness.
Manifold MarketsThe FDA will approve a drug for the treatment of senescence (aging) before the end of the decade (before 2030)
Manifold MarketsWill the FDA approve Viagra as a treatment for Alzheimer's before 2030?
Manifold MarketsWill FDA approve an “AI doctor” for primary care before 2030?
Manifold MarketsWill the FDA approve any psychedelic substance for medical use this year?
KalshiWill the FDA approve retatrutide?
KalshiKurallar
If the FDA approves VERVE-102 for marketing before Jan 1, 2035, then the market resolves to Yes. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute approvals that trigger the Payout Criterion: Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval…
Uzlaşma kaynağı:Food and Drug Administration
Her sonucun kuralı
- Before 2035
- If the FDA approves VERVE-102 for marketing before Jan 1, 2035, then the market resolves to Yes. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute approvals that trigger the Payout Criterion: Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval…
- Before 2034
- If the FDA approves VERVE-102 for marketing before Jan 1, 2034, then the market resolves to Yes. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute approvals that trigger the Payout Criterion: Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval…
- Before 2033
- If the FDA approves VERVE-102 for marketing before Jan 1, 2033, then the market resolves to Yes. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute approvals that trigger the Payout Criterion: Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval…
- Before 2032
- If the FDA approves VERVE-102 for marketing before Jan 1, 2032, then the market resolves to Yes. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute approvals that trigger the Payout Criterion: Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval…
- Before 2031
- If the FDA approves VERVE-102 for marketing before Jan 1, 2031, then the market resolves to Yes. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute approvals that trigger the Payout Criterion: Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval…
- Before 2030
- If the FDA approves VERVE-102 for marketing before Jan 1, 2030, then the market resolves to Yes. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute approvals that trigger the Payout Criterion: Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval…
